DALLAS– SpotSee, a global leader in condition-indicating and monitoring solutions, today announced the launch of TempMonitor™, a simple and affordable single-use temperature indicator designed specifically for patients who rely on insulin and Glucagon-like, peptide-1 (GLP-1) medications. TempMonitor helps distributors and patients know that their refrigerated medications have remained within the manufacturers’ recommended temperature ranges. The product will be on display at LogiPharma 2024, April 16 to 18 at Centre de Congrès de Lyon in Lyon, France, booth #39.
TempMonitor uses SpotSee’s WarmMark® technology to provide visual evidence if a medication is exposed to unacceptable temperature levels. These mini single-use indicators have a simple color-changing mechanism that alerts users when the temperature exceeds 30 degrees Celsius (86 degrees Fahrenheit), signaling possible compromise of product quality.
“At SpotSee we are focused on building solutions that span from pallet to patient and SpotSee’s TempMonitor addresses the critical need for monitoring the storage of patient’s temperature-sensitive medication, including Insulin and GLP-1s,” said Tony Fonk, President and CEO of SpotSee. “We recognize the challenges faced by patients and their families who depend on these types of medications every day, all around the world. By using TempMonitor, patients can gain peace of mind knowing that their medications are stored and transported within the recommended temperature range.”
The window of the TempMonitor indicator will stay white as long as no evidence of temperature excursions exist. But if the temperature climbs beyond 30 degrees Celsius (86 degrees Fahrenheit) within 30 minutes, the indicator will show red – signaling that the product was exposed to higher than recommended conditions. In this way, patients know how long the product had been exposed above the threshold temperature.
